MX353422B - Análogos de 2'-cloronucleósido para infección por vhc. - Google Patents

Análogos de 2'-cloronucleósido para infección por vhc.

Info

Publication number
MX353422B
MX353422B MX2015004348A MX2015004348A MX353422B MX 353422 B MX353422 B MX 353422B MX 2015004348 A MX2015004348 A MX 2015004348A MX 2015004348 A MX2015004348 A MX 2015004348A MX 353422 B MX353422 B MX 353422B
Authority
MX
Mexico
Prior art keywords
compounds
hcv infection
nucleoside analogs
chloro
compositions
Prior art date
Application number
MX2015004348A
Other languages
English (en)
Other versions
MX2015004348A (es
Inventor
Alexander Mayes Benjamin
M Moussa Adel
Gosselin Gilles
Claude Parsy Christophe
Alexandre Francois-Rene
Rahali Houcine
Griffon Jean-François
Surleraux Dominique
B Dousson Cyril
Pierra Claire
James Stewart Alistair
Dukhan David
Original Assignee
Idenix Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49354990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX353422(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idenix Pharmaceuticals Llc filed Critical Idenix Pharmaceuticals Llc
Publication of MX2015004348A publication Critical patent/MX2015004348A/es
Publication of MX353422B publication Critical patent/MX353422B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Abstract

Se proporcionan en la presente compuestos, composiciones y métodos para el tratamiento de infecciones por Flaviviridae, incluyendo infecciones por VHC. En ciertas modalidades, se describen compuestos y composiciones de derivados de nucleósidos, las cuales pueden administrarse ya sea solas o en combinación con otros agentes anti-virales. En ciertas modalidades, los compuestos son 2´-cloronucleósidos de acuerdo con la Fórmula 2001: (2001); o una sal, solvato, forma estereoisomérica, forma tautomérica o forma polimórfica farmacéuticamente aceptable del mismo, en donde B, Z y PD son como se describen en la presente.
MX2015004348A 2012-10-08 2013-10-07 Análogos de 2'-cloronucleósido para infección por vhc. MX353422B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261711131P 2012-10-08 2012-10-08
US201361807249P 2013-04-01 2013-04-01
PCT/US2013/063731 WO2014058801A1 (en) 2012-10-08 2013-10-07 2'-chloro nucleoside analogs for hcv infection

Publications (2)

Publication Number Publication Date
MX2015004348A MX2015004348A (es) 2015-10-29
MX353422B true MX353422B (es) 2018-01-12

Family

ID=49354990

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015004348A MX353422B (es) 2012-10-08 2013-10-07 Análogos de 2'-cloronucleósido para infección por vhc.

Country Status (30)

Country Link
US (2) US10513534B2 (es)
EP (1) EP2906579B1 (es)
JP (1) JP6495822B2 (es)
KR (1) KR102001280B1 (es)
CN (2) CN111848711A (es)
AP (1) AP2015008384A0 (es)
AU (1) AU2013329521B2 (es)
BR (1) BR112015007698A2 (es)
CA (1) CA2887578A1 (es)
CL (1) CL2015000870A1 (es)
CR (1) CR20150199A (es)
DO (1) DOP2015000079A (es)
EA (1) EA030189B8 (es)
EC (1) ECSP15015737A (es)
ES (1) ES2674980T3 (es)
GE (1) GEP201706723B (es)
GT (1) GT201500086A (es)
HK (1) HK1207647A1 (es)
IL (1) IL238088A0 (es)
MD (1) MD20150036A2 (es)
MX (1) MX353422B (es)
NI (1) NI201500049A (es)
NZ (1) NZ706985A (es)
PE (1) PE20151318A1 (es)
PH (1) PH12015500749A1 (es)
SG (1) SG11201502750UA (es)
TN (1) TN2015000117A1 (es)
TR (1) TR201809048T4 (es)
WO (1) WO2014058801A1 (es)
ZA (1) ZA201502545B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CN1315862C (zh) 2000-05-26 2007-05-16 艾登尼科斯（开曼）有限公司 处理黄病毒和瘟病毒的方法和组合物
EP1576138B1 (en) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
CA2843324A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
PE20150132A1 (es) 2012-05-22 2015-02-14 Idenix Pharmaceuticals Inc Compuestos d-aminoacidos para enfermedad hepatica
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
CA2871547C (en) 2012-05-25 2021-05-25 Janssen R&D Ireland Uracyl spirooxetane nucleosides
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
AP2015008384A0 (en) 2012-10-08 2015-04-30 Univ Montpellier Ct Nat De La Rech Scient 2'-Chloro nucleoside analogs for hcv infection
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
WO2014137930A1 (en) * 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
JP6476591B2 (ja) * 2013-06-05 2019-03-06 セントラル硝子株式会社 （２Ｒ）−２−フルオロ−２−Ｃ−メチル−Ｄ−リボノ−γ−ラクトン類の製造方法
WO2015017713A1 (en) * 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
US20160271160A1 (en) * 2013-10-17 2016-09-22 Medivir Ab Hcv polymerase inhibitors
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015134780A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
WO2016057866A1 (en) 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2016064797A1 (en) 2014-10-20 2016-04-28 Merck Sharp & Dohme Corp. Process for making nucleoside phosphoramidate compounds
AU2016226647A1 (en) * 2015-03-02 2017-09-21 Medivir Ab Nucleotide phosphoramidate formulation
CN107531739A (zh) * 2015-03-02 2018-01-02 美迪维尔公司 作为用于治疗丙型肝炎的hcv抑制剂的核苷酸衍生物
US10618926B2 (en) 2015-04-02 2020-04-14 Merck Sharp & Dohme Process for making phosphoramidate protected nucleoside compounds
JP6743135B2 (ja) 2015-09-02 2020-08-19 アッヴィ・インコーポレイテッド 抗ウィルス性テトラヒドロフラン誘導体
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CN106478753A (zh) 2015-09-16 2017-03-08 博瑞生物医药（苏州）股份有限公司 一种nuc‑1031单一异构体的制备方法和用途
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN105348345A (zh) * 2015-12-15 2016-02-24 杭州和正医药有限公司 一种含有硫普罗宁结构的前药、其制备方法、药物组合物及其用途
US10214554B2 (en) 2016-02-08 2019-02-26 Merck Sharp & Dohme Corp. Process for making chloro-substituted nucleoside phosphoramidate compounds
WO2017223020A1 (en) * 2016-06-20 2017-12-28 Merck Sharp & Dohme Corp. Cyclic phosphate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2017223012A1 (en) 2016-06-20 2017-12-28 Merck Sharp & Dohme Corp. Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases
AU2017324939B2 (en) 2016-09-07 2021-10-14 Atea Pharmaceuticals, Inc. 2'-substituted-N6-substituted purine nucleotides for RNA virus treatment
EP3541825A1 (en) * 2016-11-21 2019-09-25 Idenix Pharmaceuticals LLC. Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
WO2019140365A1 (en) * 2018-01-12 2019-07-18 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
WO2019199756A1 (en) 2018-04-09 2019-10-17 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
US11292810B2 (en) 2018-12-18 2022-04-05 Merck Sharp & Dohme Corp. Inclusion complexes of an HCV NS5B inhibitor and uses thereof
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CN115894458A (zh) * 2022-08-31 2023-04-04 合肥华纳生物医药科技有限公司 一种新型修饰核苷及其在核酸药物中的应用

Family Cites Families (286)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3480613A (en) 1967-07-03 1969-11-25 Merck & Co Inc 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
US5443965A (en) 1990-04-06 1995-08-22 Genelabs Incorporated Hepatitis C virus epitopes
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE4207363A1 (de) 1992-03-04 1993-09-09 Max Delbrueck Centrum Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung
US5610054A (en) 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US6423489B1 (en) 1992-09-10 2002-07-23 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
US6995146B2 (en) 1992-09-10 2006-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US6433159B1 (en) 1992-09-10 2002-08-13 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus associated diseases
AU680435B2 (en) 1992-09-10 1997-07-31 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US6391542B1 (en) 1992-09-10 2002-05-21 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
ATE181557T1 (de) 1993-02-24 1999-07-15 Jui H Wang Zusammensetzungen und methoden zur anwendung von reaktiven antiviralen polymeren
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
EP0773029A4 (en) 1993-07-19 1997-09-03 Tokyo Tanabe Co HEPATITIS C VIRUS PROLIFERATION INHIBITOR
DE4415539C2 (de) 1994-05-03 1996-08-01 Osama Dr Dr Med Omer Pflanzen mit virustatischer und antiviraler Wirkung
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE4432623A1 (de) 1994-09-14 1996-03-21 Huels Chemische Werke Ag Verfahren zur Bleichung von wäßrigen Tensidlösungen
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
JP3786447B2 (ja) 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
JP2000506010A (ja) 1996-02-29 2000-05-23 イミューソル インコーポレイテッド Ｃ型肝炎ウイルスリボザイム
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5830905A (en) 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
US5891874A (en) 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5837257A (en) 1996-07-09 1998-11-17 Sage R&D Use of plant extracts for treatment of HIV, HCV and HBV infections
GB9617177D0 (en) 1996-08-15 1996-09-25 Kvaerner H & G Offshore Ltd Downhole valve actuation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
JP3927630B2 (ja) 1996-09-27 2007-06-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウイルス感染症の予防・治療剤
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
CZ298749B6 (cs) 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
IL119833A (en) 1996-12-15 2001-01-11 Lavie David Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
WO1998027980A2 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
GB9708611D0 (en) 1997-04-28 1997-06-18 Univ Cardiff Chemical compounds
ES2200358T3 (es) 1997-06-30 2004-03-01 MERZ PHARMA GMBH & CO. KGAA 1-amino-alquilciclohexanos antagonistas del receptor de nmda.
JP4452401B2 (ja) 1997-08-11 2010-04-21 ベーリンガー インゲルハイム （カナダ） リミテッド Ｃ型肝炎ウイルス阻害ペプチドアナログ
IL138037A0 (en) 1998-02-25 2001-10-31 Univ Emory 2'-fluoronucleosides
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6833361B2 (en) 1998-05-26 2004-12-21 Ribapharm, Inc. Nucleosides having bicyclic sugar moiety
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
GB9821058D0 (en) 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
CA2362662A1 (en) 1999-02-12 2000-08-17 Glaxo Group Limited Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2389745C (en) 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
PL364995A1 (en) 2000-02-18 2004-12-27 Shire Biochem Inc. Method for the treatment or prevention of flavivirus
US7094770B2 (en) 2000-04-13 2006-08-22 Pharmasset, Ltd. 3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
GB0009486D0 (en) 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
GB0011203D0 (en) 2000-05-09 2000-06-28 Univ Cardiff Chemical compounds
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CN1315862C (zh) 2000-05-26 2007-05-16 艾登尼科斯（开曼）有限公司 处理黄病毒和瘟病毒的方法和组合物
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
US20020068702A1 (en) 2000-07-21 2002-06-06 Marguerita Lim-Wilby Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
MXPA03000626A (es) 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
CN1133642C (zh) 2000-10-09 2004-01-07 清华大学 核苷5’-硫代磷酰氨基酸酯化合物
CN1646141B (zh) 2000-10-18 2014-06-25 吉利德制药有限责任公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
CN100391967C (zh) 2000-11-20 2008-06-04 布里斯托尔-迈尔斯斯奎布公司 丙型肝炎三肽抑制剂
AU3659102A (en) 2000-12-12 2002-06-24 Schering Corp Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
AU2002230763A1 (en) 2000-12-13 2008-01-03 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
US6727366B2 (en) 2000-12-13 2004-04-27 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
AU2002232660A1 (en) 2000-12-15 2002-06-24 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
EP1707571B1 (en) 2001-01-22 2011-09-28 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
BR0207746A (pt) 2001-03-01 2004-06-29 Pharmasset Ltd Método para a sìntese de 2',3'-didesoxi-2',3'-didesidronucleosìdeo
US20040209831A1 (en) 2002-02-20 2004-10-21 Mcswiggen James RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
GB0112617D0 (en) 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
WO2003000713A1 (en) 2001-06-21 2003-01-03 Glaxo Group Limited Nucleoside compounds in hcv
US7022323B2 (en) 2001-06-26 2006-04-04 Progenics Pharmaceuticals, Inc. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
US7138376B2 (en) 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
WO2003026675A1 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US7323453B2 (en) 2002-02-13 2008-01-29 Merck & Co., Inc. Methods of inhibiting orthopoxvirus replication with nucleoside compounds
ATE519774T1 (de) 2002-02-20 2011-08-15 Sirna Therapeutics Inc Durch eine störung der rna vermittelte inhibierung der genexpression des hepatitis c virus (hcv) mit kurzer, störender nukleinsäure (short interfering nucleic acid, sina)
WO2003072757A2 (en) 2002-02-28 2003-09-04 Biota, Inc. Nucleotide mimics and their prodrugs
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
DE60324552D1 (en) 2002-05-20 2008-12-18 Bristol Myers Squibb Co Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
AU2003299519A1 (en) 2002-05-20 2004-05-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
PL211889B1 (pl) 2002-05-20 2012-07-31 Bristol Myers Squibb Co Pochodna heterocyklosulfonamidowa, kompozycja ją zawierająca oraz ich zastosowanie
WO2003100017A2 (en) 2002-05-24 2003-12-04 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
AU2003251524A1 (en) 2002-06-17 2003-12-31 Isis Pharmaceuticals, Inc. Carbocyclic nucleoside analogs as RNA-antivirals
EP1551421A2 (en) 2002-06-21 2005-07-13 Merck & Co. Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
JP2006512288A (ja) 2002-06-27 2006-04-13 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体
US7456155B2 (en) 2002-06-28 2008-11-25 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CN103319554A (zh) 2002-06-28 2013-09-25 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
AP2005003211A0 (en) 2002-06-28 2005-03-31 Idenix Cayman Ltd 1'-,2'-and 3'-modified nucleoside derivatives for treating flaviviridae infections.
JP2005533108A (ja) 2002-07-16 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ依存性ｒｎａウイルスポリメラーゼの阻害剤としてのヌクレオシド誘導体
US7323449B2 (en) 2002-07-24 2008-01-29 Merck & Co., Inc. Thionucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US20040067877A1 (en) 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
US20040229840A1 (en) 2002-10-29 2004-11-18 Balkrishen Bhat Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
EP1576138B1 (en) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
KR20050109918A (ko) 2002-12-12 2005-11-22 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드의 제조 방법
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
AR043006A1 (es) 2003-02-12 2005-07-13 Merck & Co Inc Proceso para preparar ribonucleosidos ramificados
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
WO2004096286A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Antiviral phosphonate analogs
EP1656093A2 (en) 2003-05-14 2006-05-17 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
ES2726998T3 (es) 2003-05-30 2019-10-11 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
CN1809582A (zh) 2003-06-19 2006-07-26 弗·哈夫曼-拉罗切有限公司 制备4＇－叠氮基核苷衍生物的方法
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
US20050043266A1 (en) 2003-07-25 2005-02-24 Sumedha Jayasena Short interfering RNA as an antiviral agent for hepatitis C
AU2004282148A1 (en) 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incoporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
SG170825A1 (en) 2004-03-04 2011-05-30 Leuven K U Res & Dev Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
CA2568379A1 (en) 2004-06-15 2005-12-29 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
BRPI0512360A (pt) 2004-06-23 2008-03-11 Idenix Cayman Ltd derivados de 5-aza-7-deazapurina para o tratamento de flaviviridae
US20070265222A1 (en) 2004-06-24 2007-11-15 Maccoss Malcolm Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
JP4914348B2 (ja) 2004-06-28 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類似体
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
DK2258376T3 (en) 2004-07-27 2019-04-15 Gilead Sciences Inc Phosphonate analogues of HIV inhibitor compounds
CN101044151B (zh) 2004-08-23 2011-01-19 弗·哈夫曼-拉罗切有限公司 抗病毒的4＇-叠氮基-核苷
ATE513844T1 (de) 2004-08-27 2011-07-15 Schering Corp Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
AU2005317081A1 (en) 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection
US8399428B2 (en) 2004-12-09 2013-03-19 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
AP2007004128A0 (en) 2005-02-28 2007-08-31 Genelabs Tech Inc Tricyclic-nucleoside compounds for treating viral infections
AU2006222563A1 (en) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
WO2007144686A1 (en) 2005-03-09 2007-12-21 Idenix (Cayman) Limited Nucleosides with non-natural bases as anti-viral agents
WO2006116557A1 (en) * 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
CA2606195C (en) 2005-05-02 2015-03-31 Merck And Co., Inc. Hcv ns3 protease inhibitors
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
CA2618560A1 (en) 2005-08-09 2007-02-22 Merck & Co., Inc. Ribonucleoside cyclic acetal derivatives for the treatment of rna-dependent rna viral infection
EP1915053A2 (en) 2005-08-12 2008-04-30 Merck & Co., Inc. Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
EP1928475B1 (en) 2005-08-15 2018-05-23 Riboscience LLC Antiviral phosphoramidates of 4'-c-azido-substituted pronucleotides
CA2904692A1 (en) 2005-09-26 2007-04-05 Gilead Pharmasset Llc Modified 4'-nucleosides as antiviral agents
WO2007067364A2 (en) 2005-12-02 2007-06-14 Yale University Methods of treating cancer and other conditions or disease states using l-cytosine nucleoside analogs
EP1957510A1 (en) 2005-12-09 2008-08-20 F.Hoffmann-La Roche Ag Antiviral nucleosides
EP1976382B1 (en) 2005-12-23 2013-04-24 IDENIX Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
AU2007215114A1 (en) 2006-02-14 2007-08-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
JP2009532411A (ja) 2006-04-04 2009-09-10 エフ．ホフマン−ラ ロシュ アーゲー Ｈｃｖ治療のための３’，５’−ジ−ｏ−アシル化ヌクレオシド
US7842672B2 (en) 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
CA2666098C (en) 2006-10-10 2012-09-25 Steven D. Axt Preparation of nucleosides ribofuranosyl pyrimidines
AU2007306405A1 (en) 2006-10-10 2008-04-17 Medivir Ab HCV nucleoside inhibitor
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
ATE478084T1 (de) 2006-12-11 2010-09-15 Hoffmann La Roche Verfahren zur herstellung von 4'- azidocytidinderivaten
EP2120565B1 (en) 2006-12-20 2012-11-28 Merck Sharp & Dohme Corp. Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
WO2008083465A1 (en) 2007-01-08 2008-07-17 University Health Network Pyrimidine derivatives as anticancer agents
WO2008100447A2 (en) 2007-02-09 2008-08-21 Gilead Sciences, Inc. Nucleoside analogs for antiviral treatment
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2008143846A1 (en) 2007-05-14 2008-11-27 Rfs Pharma, Llc Azido purine nucleosides for treatment of viral infections
US20090048189A1 (en) 2007-08-15 2009-02-19 Genelabs Technologies, Inc. Tricyclic-nucleoside compounds for treating viral infections
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US20090176732A1 (en) 2007-12-21 2009-07-09 Alios Biopharma Inc. Protected nucleotide analogs
CN102123716B (zh) 2008-04-03 2013-09-18 春堤公司 用于治疗病毒感染的化合物和方法
US8008264B2 (en) 2008-04-23 2011-08-30 Gilead Sciences, Inc. 1′-substituted carba-nucleoside analogs for antiviral treatment
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
TW201004632A (en) 2008-07-02 2010-02-01 Idenix Pharmaceuticals Inc Compounds and pharmaceutical compositions for the treatment of viral infections
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
GB0815968D0 (en) 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
EP2342616A2 (en) 2008-09-23 2011-07-13 Alnylam Pharmaceuticals Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
CN102325783A (zh) * 2008-12-23 2012-01-18 法莫赛特股份有限公司 嘌呤核苷的合成
CA2748034A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Purified 2'-deoxy'2'-fluoro-2'-c-methyl-nucleoside-phosphoramidate prodrugs for the treatment of viral infections
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
EA201170915A1 (ru) 2009-01-09 2012-02-28 Юниверсити Колледж Оф Кардифф Консалтентс Лимитед Фосфорамидатные производные гуанозиновых нуклеозидов для лечения вирусных инфекций
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
WO2010091386A2 (en) 2009-02-06 2010-08-12 Rfs Pharma, Llc Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
ES2628842T3 (es) 2009-02-10 2017-08-04 Gilead Sciences, Inc. Método para la preparación de tieno[3,4-d]pirimidin-7-il ribósidos
WO2010108135A1 (en) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Protected nucleotide analogs
AP2011005929A0 (en) 2009-03-20 2011-10-31 Alios Biopharma Inc Substituted nucleoside and nucleotide analogs.
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TW201107342A (en) 2009-05-20 2011-03-01 Chimerix Inc Compounds, compositions and methods for treating viral infection
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
AU2010270715C1 (en) 2009-07-06 2016-03-17 Trilink Biotechnologies Chemically modified ligase cofactors, donors and acceptors
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US20100077085A1 (en) 2009-09-23 2010-03-25 Joseph Chyam Cohen Systems and method for configuring display resolution in a terminal server environment
US8552021B2 (en) 2009-09-29 2013-10-08 Janssen Products, L.P. Phosphoramidate derivatives of nucleosides
US8816074B2 (en) 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
MX2012005601A (es) 2009-11-16 2012-08-01 Univ Georgia Nucleosidos carboxiclicos de 2'-fluoro-6'-metileno y metodos para tratar infecciones virales.
PL2528930T3 (pl) 2010-01-28 2014-03-31 Riboscience Llc 4`-azydonukleozydy jako związki przeciw hcv
MX2012010252A (es) 2010-03-04 2013-02-01 Enanta Pharm Inc Agentes farmaceuticos en combinacion como inhibidores de la replicacion del virus de hepatitis c (hcv).
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
SG184323A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasett Llc Stereoselective synthesis of phosphorus containing actives
MX2012011222A (es) * 2010-04-01 2013-01-18 Centre Nat Rech Scient Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales.
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
WO2011156757A1 (en) 2010-06-10 2011-12-15 Gilead Sciences, Inc. Combination of anti-hcv compounds with ribavirin for the treatment of hcv
JP5937073B2 (ja) * 2010-07-19 2016-06-22 ギリード・サイエンシズ・インコーポレーテッド ジアステレオマーとして純粋なホスホルアミデートプロドラッグの調製方法
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
US20120070411A1 (en) 2010-09-22 2012-03-22 Alios Biopharma, Inc. Substituted nucleotide analogs
CA2812962C (en) 2010-09-22 2020-03-31 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
KR20130110170A (ko) 2010-09-22 2013-10-08 앨리오스 바이오파마 인크. 치환된 뉴클레오타이드 유사체
WO2012048013A2 (en) 2010-10-06 2012-04-12 Inhibitex, Inc. Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
PL2638054T3 (pl) 2010-11-10 2015-05-29 Janssen Products Lp Fosforoamidany nukleozydów uracylo-spirooksetanowych
US9006209B2 (en) 2010-11-10 2015-04-14 Janssen Products, Lp Uracyl spirooxetane nucleoside phosphoramidates
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
JP5891241B2 (ja) 2010-12-20 2016-03-22 ギリアード サイエンシーズ， インコーポレイテッド Ｈｃｖを処置するための組合せ
AU2011349278C1 (en) * 2010-12-22 2017-01-19 Alios Biopharma, Inc. Cyclic nucleotide analogs
WO2012092484A2 (en) 2010-12-29 2012-07-05 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
US9095599B2 (en) 2011-01-03 2015-08-04 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
US9156874B2 (en) 2011-01-03 2015-10-13 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
US9085599B2 (en) 2011-03-16 2015-07-21 Enanta Pharmaceuticals, Inc. 2′allene-substituted nucleoside derivatives
CA2843324A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
CA2832449A1 (en) 2011-04-13 2012-10-18 Vinay GIRIJAVALLABHAN 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EA201391264A1 (ru) 2011-04-13 2014-03-31 Джилид Сайэнс, Инк. 1'-замещенные пиримидиновые n-нуклеозидные аналоги для противовирусного лечения
WO2012142085A1 (en) * 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
RU2013125713A (ru) 2011-05-19 2015-06-27 Рфс Фарма, Ллк Пуринмонофосфатные пролекарства для лечения вирусных инфекций
EP2731433A4 (en) 2011-07-13 2014-12-31 Merck Sharp & Dohme 5'-SUBSTITUTED NUCLEOSIDE ANALOGUES AND METHODS OF USE FOR THE TREATMENT OF VIRAL DISEASES
WO2013009735A1 (en) 2011-07-13 2013-01-17 Merck Sharp & Dohme Corp. 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
CN103987712B (zh) 2011-07-19 2016-05-04 河南美泰宝生物制药有限公司 2’，3’-二脱氧-2’-α-氟-2’-β-C-甲基核苷和其前药
EP2755985B1 (en) 2011-09-12 2017-11-01 Idenix Pharmaceuticals LLC Compounds and pharmaceutical compositions for the treatment of viral infections
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
WO2013044030A1 (en) 2011-09-23 2013-03-28 Enanta Pharmaceuticals, Inc. 2'-chloroacetylenyl substituted nucleoside derivatives
AR089650A1 (es) 2011-10-14 2014-09-10 Idenix Pharmaceuticals Inc Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013084165A1 (en) 2011-12-05 2013-06-13 Medivir Ab Hcv polymerase inhibitors
HUE033727T2 (en) 2011-12-20 2018-01-29 Riboscience Llc 2 ', 4'-difluoro-2'-methyl-substituted nucleoside derivatives as inhibitors of HCV RNA replication
SI2794628T1 (sl) 2011-12-20 2017-07-31 Riboscience Llc 4'-azido-3'-fluoro substituirani nukleozidni derivati kot inhibitorji podvojevanja RNA HCV
WO2013106344A1 (en) 2012-01-12 2013-07-18 Ligand Pharmaceuticals, Inc. 2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5'
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
PE20150132A1 (es) 2012-05-22 2015-02-14 Idenix Pharmaceuticals Inc Compuestos d-aminoacidos para enfermedad hepatica
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
AP2015008384A0 (en) 2012-10-08 2015-04-30 Univ Montpellier Ct Nat De La Rech Scient 2'-Chloro nucleoside analogs for hcv infection
EP2909210A4 (en) 2012-10-17 2016-04-06 Merck Sharp & Dohme 2'-DISUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THE USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
WO2014059901A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
US20140112886A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
US20140140952A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Sp-Nucleoside Analog
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
WO2014124430A1 (en) 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
RU2534613C2 (ru) 2013-03-22 2014-11-27 Александр Васильевич Иващенко Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
CN103848876B (zh) 2013-03-25 2016-05-11 安徽贝克联合制药有限公司 一种核苷磷酰胺前药及其制备方法和其应用
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
WO2014204831A1 (en) 2013-06-18 2014-12-24 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
US20160271162A1 (en) 2013-11-01 2016-09-22 Idenix Pharmacueticals, Llc D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
WO2015077360A2 (en) 2013-11-20 2015-05-28 Idenix Pharmaceuticals, Inc. Cyclopentane and cyclopentene nucleoside analogs for the treatment of hcv
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
WO2015081133A2 (en) 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. Nucleotides for the treatment of liver cancer
CN103848877B (zh) 2013-12-16 2016-08-24 安徽贝克联合制药有限公司 核苷环磷酸酯化合物及其制备方法和其应用
WO2015095305A1 (en) 2013-12-17 2015-06-25 Idenix Pharmaceuticals, Inc. Production of cyclic phosphate, phosphoramidate, thiophosphate, and phosphonate nucleoside compounds
EP3083654A1 (en) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC 4'-or nucleosides for the treatment of hcv
WO2015134780A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv

Also Published As

Publication number Publication date
EA030189B8 (ru) 2018-10-31
MX2015004348A (es) 2015-10-29
US10513534B2 (en) 2019-12-24
ZA201502545B (en) 2017-08-30
PH12015500749A1 (en) 2015-05-25
NI201500049A (es) 2016-02-16
JP6495822B2 (ja) 2019-04-03
DOP2015000079A (es) 2015-11-30
AP2015008384A0 (en) 2015-04-30
US20140099283A1 (en) 2014-04-10
CA2887578A1 (en) 2014-04-17
SG11201502750UA (en) 2015-06-29
WO2014058801A1 (en) 2014-04-17
KR102001280B1 (ko) 2019-07-17
EA201500304A1 (ru) 2016-01-29
TN2015000117A1 (en) 2016-06-29
EP2906579A1 (en) 2015-08-19
GT201500086A (es) 2018-12-19
TR201809048T4 (tr) 2018-07-23
IL238088A0 (en) 2015-05-31
MD20150036A2 (ro) 2015-08-31
AU2013329521B2 (en) 2018-04-19
HK1207647A1 (en) 2016-02-05
ECSP15015737A (es) 2015-12-31
US20160083413A1 (en) 2016-03-24
EP2906579B1 (en) 2018-04-18
PE20151318A1 (es) 2015-10-03
AU2013329521A1 (en) 2015-05-28
EA030189B1 (ru) 2018-07-31
GEP201706723B (en) 2017-08-25
CN111848711A (zh) 2020-10-30
KR20150084830A (ko) 2015-07-22
BR112015007698A2 (pt) 2017-08-22
CL2015000870A1 (es) 2015-11-13
NZ706985A (en) 2018-08-31
CR20150199A (es) 2015-09-01
CN104936970A (zh) 2015-09-23
JP2015535853A (ja) 2015-12-17
ES2674980T3 (es) 2018-07-05

Similar Documents

Publication Publication Date Title
PH12015500749A1 (en) 2`chloro nucleoside analogs for hcv infection
WO2015077360A3 (en) Cyclopentane and cyclopentene nucleoside analogs for the treatment of hcv
PH12018501736A1 (en) Tetracyclic pyridone compounds as antivirals
TN2013000421A1 (en) 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EA201492204A1 (ru) Нуклеозиды на основе урацила и спирооксетана
WO2015081133A3 (en) Nucleotides for the treatment of liver cancer
HK1166788A1 (es)
WO2012142093A3 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
HRP20150725T1 (hr) Kondenzirani imidazolilimidazoli kao antivirusni spojevi
NZ748966A (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
MX2020003055A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
MX2015005949A (es) Nucleosidos que contienen aza-azucar antiviral.
PH12014502603A1 (en) D-amino acid compounds for liver disease
IN2012DN01855A (es)
WO2012142523A3 (en) 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
PH12015501560A1 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
WO2012174312A3 (en) Benzimidazole derivatives as antiviral agents
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
MX2014009546A (es) Compuestos antivirales con una porcion heterotriciclica.
MX2012006026A (es) Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus.
MX2014001721A (es) Analogos de quinazolinona y usos de los analogos de quinazolinona para tratar o prevenir ciertas infecciones virales.
TH124704B (th) สารประกอบและองค์ประกอบทางเภสัชกรรม สำหรับรักษาการติดเชื้อไวรัส
TH124704A (th) สารประกอบและองค์ประกอบทางเภสัชกรรม สำหรับรักษาการติดเชื้อไวรัส
UA107801C2 (en) Derivatives of thiophene-2-carboxylic acid inhibitors viruses flaviviridae

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: THE GILLETTE COMPANY LLC

FG Grant or registration